Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Fig. 6

CtDNA is a potential biomarker for MRD detection and relapse prediction. A CtDNA monitoring results at different time points in 25 patients who achieved radiographic CR. B Gene alterations analyzed using plasma cfDNA at baseline, C2, C4, C6, and follow-up visits for patient RR821 are shown in detail. Radiographic images of the corresponding time points are shown below. RFS, relapse-free survival; PD, progression disease; V1, the first follow-up visit; V2, the second follow-up visit; V3, the third follow-up visit; V4, the fourth follow-up visit

Back to article page